- Home
- QLGN vs SNPX Comparison
QLGN vs SNPX Comparison
Compare QLGN & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- SNPX
- Stock Information
- Founded
- QLGN 1996
- SNPX 2012
- Country
- QLGN United States
- SNPX United States
- Employees
- QLGN N/A
- SNPX N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- QLGN Health Care
- SNPX Health Care
- Exchange
- QLGN Nasdaq
- SNPX Nasdaq
- Market Cap
- QLGN 2.8M
- SNPX 3.1M
- IPO Year
- QLGN N/A
- SNPX N/A
- Fundamental
- Price
- QLGN $3.75
- SNPX $2.41
- Analyst Decision
- QLGN
- SNPX Strong Buy
- Analyst Count
- QLGN 0
- SNPX 1
- Target Price
- QLGN N/A
- SNPX $14.00
- AVG Volume (30 Days)
- QLGN 10.5K
- SNPX 19.8K
- Earning Date
- QLGN 07-01-2025
- SNPX 05-15-2025
- Dividend Yield
- QLGN N/A
- SNPX N/A
- EPS Growth
- QLGN N/A
- SNPX N/A
- EPS
- QLGN N/A
- SNPX N/A
- Revenue
- QLGN N/A
- SNPX N/A
- Revenue This Year
- QLGN N/A
- SNPX N/A
- Revenue Next Year
- QLGN N/A
- SNPX N/A
- P/E Ratio
- QLGN N/A
- SNPX N/A
- Revenue Growth
- QLGN N/A
- SNPX N/A
- 52 Week Low
- QLGN $2.85
- SNPX $1.84
- 52 Week High
- QLGN $29.44
- SNPX $5.05
- Technical
- Relative Strength Index (RSI)
- QLGN 51.20
- SNPX 49.39
- Support Level
- QLGN $3.65
- SNPX $2.51
- Resistance Level
- QLGN $3.98
- SNPX $2.76
- Average True Range (ATR)
- QLGN 0.14
- SNPX 0.18
- MACD
- QLGN -0.01
- SNPX 0.03
- Stochastic Oscillator
- QLGN 51.32
- SNPX 45.10
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.